Long term response to apalutamide and other updates impacting patients with nmCR...
Prof Axel Merseburger and Prof Matthew Smith
22 Feb 2021
mCRPC and nmCRPC: Combinations and latest data, what does COVID mean for early t...
Dr Eleni Efstathiou, Prof Stefan Oudard Prof Boris Hadaschik and Prof Gerhardt A...
19 Feb 2021
Diagnosis, testing and biomarkers in the individualisation of patient care with ...
Prof Andrea Necchi and Prof Eva Compérat
18 Feb 2021
Nurse's perspective on PARP inhibitors and personalised medicine in prostate can...
Louisa Fleure - Guy's and St Thomas' NHS Trust, London, UK
17 Feb 2021
TALAPRO-1: phase II study of talazoparib in patients with DNA damage repair alte...
Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
15 Feb 2021
ASCO GU 2021: Renal cancer roundup
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
15 Feb 2021
TITAN: Update and where next for patients with hormone sensitive PC
Prof Axel Merseburger and Prof Kim Chi
15 Feb 2021
OncoAlert and ecancer weekly roundup for February 07 - 13, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
15 Feb 2021
OncoAlert and ecancer weekly roundup for February 01 - 06, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
9 Feb 2021
Emergence of PARP inhibitors in prostate cancer
Kenrick Ng - Senior Specialist Registrar in Medical Oncology, UCL Hospitals, Lon...
5 Feb 2021
Advances and treatment strategies for metastatic hormone-sensitive prostate canc...
Kenrick Ng - Senior Specialist Registrar in Medical Oncology, UCL Hospitals, Lon...
5 Feb 2021
Outcomes of black and white men with prostate cancer in an equal access healthca...
Kenrick Ng - Senior Specialist Registrar in Medical Oncology, UCL Hospitals, Lon...
5 Feb 2021
